Skip to main content
. 2021 Sep 9;3(3):zcab035. doi: 10.1093/narcan/zcab035

Figure 1.

Figure 1.

CPT1A is overexpressed in highly proliferative ER+ breast tumors and is associated with poor overall survival. Tumor samples from the (A) TCGA (n = 1031) or (B) METABRIC (n = 1992) cohorts were dichotomized into basal-like or ER+ tumors with ER+ tumors further divided into high- and low-proliferation groups based on the PAM50 proliferation signature. Highly proliferative ER+ tumors show increased CPT1A expression (P < 0.0001, ANOVA, Tukey’s test). (C) Proteomic data from the CPTAC project (n = 77) were used to demonstrate increased Cpt1a protein expression in highly proliferative ER+ tumors (P < 0.0001, ANOVA, Tukey’s test).(D) RPPA data from ER+ tumors from the TCGA project (n = 606) demonstrate increased expression of proliferation markers (P<0.0001, unpaired t-test). High CPT1A mRNA expression was shown to correlate with poor overall survival in the (E) TCGA (P = 0.005, HR: 1.5) and (F) METABRIC (P < 0.0001, HR: 1.7) cohorts.